These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 34870494)

  • 1. System analysis of
    Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
    Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Situ Y; Zhang J; Liao W; Liang Q; Lu L; Xu Q; Chen J; Lu X; Cui Y; Shao Z; Deng L
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):196. PubMed ID: 37796681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
    Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
    Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of
    Bai J; Zheng A; Ha Y; Xu X; Yu Y; Lu Y; Zheng S; Shen Z; Luo B; Jie W
    Front Mol Biosci; 2022; 9():988777. PubMed ID: 36188228
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis.
    Situ Y; Lu X; Cui Y; Xu Q; Deng L; Lin H; Shao Z; Chen J
    Biomed Res Int; 2022; 2022():5137301. PubMed ID: 36246978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.
    Mao JX; Li JJ; Lu XY; Zhong HX; Zhao YY; Zhu LY; Fu H; Ding GS; Teng F; Chen M; Guo WY
    Int Immunopharmacol; 2024 Jul; 136():112340. PubMed ID: 38820962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-inducible protein 16 may be a biomarker and prognostic factor in renal cell carcinoma by bioinformatics analysis.
    Yu B; Zhang J; Sun Z; Cao P; Zheng X; Gao Z; Cao H; Zhang F; Wang W
    Medicine (Baltimore); 2021 Jan; 100(1):e24257. PubMed ID: 33429832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An
    Fu S; Gong B; Ding Y; Zhuang C; Chen Q; Wang S; Li Z; Ma M; Liu Y; Zhang Z; Sun T
    Comb Chem High Throughput Screen; 2022; 25(13):2278-2294. PubMed ID: 35293292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2J2 Is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
    Zou X; Mo Z
    Biomed Res Int; 2021; 2021():3771866. PubMed ID: 34258261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCF1/2/4 Are Prognostic Biomarkers Related to the Immune Infiltration of Kidney Renal Clear Cell Carcinoma.
    Chen Y; He F; Wang R; Yao M; Li Y; Guo D; He S
    Biomed Res Int; 2021; 2021():5954036. PubMed ID: 34708124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma.
    Zhou F; Shen D; Xiong Y; Cheng S; Xu H; Wang G; Qian K; Ju L; Zhang X
    Front Oncol; 2020; 10():570819. PubMed ID: 33628726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma.
    Liu Y; Cheng X; Xi P; Zhang Z; Sun T; Gong B
    BMC Urol; 2023 Apr; 23(1):54. PubMed ID: 37004005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential upstream lncRNA-miRNA-mRNA regulatory network of the ferroptosis-related gene
    Xu F; Ji S; Yang L; Li Y; Shen P
    Transl Androl Urol; 2023 Jan; 12(1):33-57. PubMed ID: 36760866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation.
    Tang Q; Wang Y; Ou L; Li J; Zheng K; Zhan H; Gu J; Zhou G; Xie S; Zhang J; Huang W; Wang S; Wang X
    Int J Biol Sci; 2021; 17(8):1925-1939. PubMed ID: 34131396
    [No Abstract]   [Full Text] [Related]  

  • 18. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-Like Receptors Serve as Biomarkers for Early Diagnosis and Prognosis Assessment of Kidney Renal Clear Cell Carcinoma by Influencing the Immune Microenvironment: Comprehensive Bioinformatics Analysis Combined With Experimental Validation.
    Zou X; Guo B; Ling Q; Mo Z
    Front Mol Biosci; 2022; 9():832238. PubMed ID: 35127830
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
    Yang J; Li H; Hu S; Zhou Y
    Aging (Albany NY); 2020 Apr; 12(8):6518-6535. PubMed ID: 32339157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.